Clinical trials: Therapeutic Drug Monitoring (TDM)
Dementia, Dementia With Lewy Bodies
Monitoring Anti-Dementia Drugs by Serum Levels
The main objective of the MONANTI study is twofold: Firstly, to determine the serum concentration (SC) the anti-dementia drugs donepezil and memantine in a broadly defined clinical population of patients suffering from dementia…
- Conditions
- Dementia, Dementia With Lewy Bodies, Dementia in Parkinsons Disease, Dementia Alzheimers
- Trial name
- MONANTI (NCT04117178)
- Testing
- Donepezil, Memantine, Measurement of serum level of anti-dementia drug
- Where
- Denmark
- Volunteers
- 132 people
- Sponsor
- Zealand University Hospital
HIV Infections
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC
The primary purpose of this study is to: 1. Demonstrate the safety and efficacy of tipranavir/ritonavir (TPV/r) among a racially diverse HIV+ population (males and females) who are three-class (nucleoside reverse transcriptase…
- Trial name
- NCT00440271
- Testing
- tipranavir, ritonavir, Optimized Background Regimen (OBR)
- Where
- 30 sites in United States, Argentina and 5 more
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Kidney Transplantation
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
The 12 Month Core Study (CRAD001A1202) was designed to evaluate the efficacy and safety comparing concentration-controlled everolimus (1.5 mg/day starting dose) with reduced dose cyclosporine and corticosteroids versus 2 g/day…
- Trial name
- NCT00658320
- Testing
- Everolimus, Mycophenolate mofetil (MMF), Basiliximab
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- Novartis
Inflammatory Bowel Diseases, Colitis, Ulcerative
Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
The purpose of this study is to determine if a relationship exists between Week 6 vedolizumab therapeutic drug monitoring (TDM) and Week 30 Faecal calprotectin (FCP).
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- VEDO TDM RWE (NCT04567628)
- Testing
- No Intervention
- Where
- Canada
- Volunteers
- 7,873 people
- Sponsor
- Takeda